Hologic Statement On USPSTF Draft Cervical Cancer Screening Guidelines Committed To Working With USPSTF And Others Within The Cervical Cancer Community In Support Of Final Screening Guidelines That Preserve All Screening Options
Hologic Statement On USPSTF Draft Cervical Cancer Screening Guidelines Committed To Working With USPSTF And Others Within The Cervical Cancer Community In Support Of Final Screening Guidelines That Preserve All Screening Options
Multiple studies and other research representative of real-world screening practices in the US demonstrate that screening women ages 30-65 with the Pap test combined with HPV test identifies more cervical pre-cancer and cancer than either test used alone.5-8 The draft recommendations reinforce the value of all three cervical cancer screening strategies for women including Pap testing for women ages 21-29 years old.9 The draft recommendations also continue to allow for shared decision-making between healthcare providers and patients and help ensure that women can continue to access the preventive care they need and deserve.Hologic, Inc., (NASDAQ:HOLX) a global leader in women's health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:
豪洛捷公司（NASDAQ：HOLX）是全球领先的女性健康公司，专注于开发创新的医疗技术，有效检测、诊断和治疗健康状况。今天发布了关于美国预防服务工作组草案指南的声明，涉及子宫颈癌筛查：
"Today's recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer," said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. "Eliminating cervical cancer is within our reach and history has shown us that safeguarding the most comprehensive screening available is critical to that effort."
"今天的建议重要地承认了Pap检测与HPV检测结合的作用，这是标准的黄金护理方法，也是识别子宫颈癌的最有效方法，" 豪洛捷诊断解决方案总裁詹妮弗·施奈德斯博士表示。 "消除子宫颈癌在我们的能力范围内，历史告诉我们，维护最全面的筛查是成功的关键。"
Once the leading cause of cancer death in women, cervical cancer mortality rates have plummeted by 70% mainly due to cervical cancer screening.1 Despite this progress, cervical cancer incidence is no longer declining and cases continue to disproportionately impact Black and Hispanic women, making a focus on routine screening and vaccination imperative.2-4
曾经是女性癌症死亡的主要原因，子宫颈癌死亡率已下降70%，主要得益于子宫颈癌筛查。尽管取得了这种进展，子宫颈癌的发病率却没有继续下降，并且病例继续对黑人和西班牙裔女性产生不成比例的影响，因此必须专注于常规筛查和疫苗接种。
Multiple studies and other research representative of real-world screening practices in the US demonstrate that screening women ages 30-65 with the Pap test combined with HPV test identifies more cervical pre-cancer and cancer than either test used alone.5-8 The draft recommendations reinforce the value of all three cervical cancer screening strategies for women including Pap testing for women ages 21-29 years old.9 The draft recommendations also continue to allow for shared decision-making between healthcare providers and patients and help ensure that women can continue to access the preventive care they need and deserve.
多项研究和其他代表美国实际筛查做法的研究表明，使用Pap检测结合HPV检测对30-65岁女性的筛查能够识别更多的子宫颈前癌和癌症，而单独使用任一测试则无法达到此效果。这些草案建议强调了针对女性的所有三种子宫颈癌筛查策略的价值，包括对21-29岁女性的Pap检测。这些草案还继续允许医疗保健提供者与患者之间进行共同决策，并帮助确保女性能够继续获得她们所需和应得的预防保健。
Hologic is committed to working with USPSTF and others within the cervical cancer community in support of final screening guidelines that preserve all screening options, improving our ability to combat this preventable cancer and save more women's lives.
豪洛捷致力于与USPSTF及其他子宫颈癌社区成员合作，支持最终筛查指南，保留所有筛查选择，提升我们对抗这种可预防癌症的能力，拯救更多女性的生命。
